CD44、EGFR、p16及其相互组合在头颈癌患者中的表达:对调强放疗结局的影响
本研究对165例头颈鳞状细胞癌(HNSCC)患者进行p16、表皮生长因子受体(EGFR)和CD44的免疫组化分析,评估其与调强放疗结局的关系。在全组及p16阴性队列中,p16阳性、CD44阴性及EGFR阴性均与更好的3年总生存和局部区域控制相关。联合分析显示CD44+/p16-、EGFR+/p16-、EGFR+/CD44+组及p16阴性队列中的EGFR+/CD44+组结局最差。多因素分析发现肿瘤分期、Karnofsky指数、p16和CD44是总生存的预后因素,临床分期和p16是局部区域控制的预后因素。
要点
- p16阳性与更好的3年总生存和局部区域控制相关。
- CD44阴性和EGFR阴性均与更好的放疗结局相关。
- CD44+/p16-、EGFR+/p16-、EGFR+/CD44+组合的放疗结局最差。
核心结论
- 本研究证实CD44和EGFR对放疗结果有负面影响,p16对放疗结果有正面影响。
研究设计与样本
- 对165例头颈鳞状细胞癌(HNSCC)患者进行p16、表皮生长因子受体(EGFR)和CD44的免疫组化分析。
主要发现
- 在全组和p16阴性队列中,p16阳性、CD44阴性及EGFR阴性均与更好的3年总生存和局部区域控制相关。
- 联合分析显示CD44+/p16-、EGFR+/p16-、EGFR+/CD44+组及p16阴性队列中的EGFR+/CD44+组结局最差。
- 多因素分析发现肿瘤分期、Karnofsky指数、p16和CD44是总生存的预后因素,临床分期和p16是局部区域控制的预后因素。
- 临床分期和Karnofsky指数影响总生存,肿瘤分期影响总生存。
- EGFR在p16阴性亚组中影响局部区域控制。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Progress in radiation treatment of head and neck squamous cell carcinoma (HNSCC) deserves the studies focused on molecular predictors that would help to enhance individually tailored treatment. METHODS: p16/epidermal growth factor receptor (EGFR)/cluster of differentiation-44 (CD44) was immunohistochemically analyzed in 165 HNSCC patients. RESULTS: In the entire group and the p16 negative cohort, better 3-year overall survival and locoregional control correlated with p16 positivity, CD44, and EGFR negativity were observed. Combined analysis revealed the worst results in the CD44+/p16-, EGFR+/p16-, and EGFR+/CD44+ groups and in the EGFR+/CD44+ within p16 negative cohort. Multivariate analysis found tumor stage, Karnofsky index, p16, and CD44 as prognostic factors of overall survival and clinical stage, and p16 as a prognostic factor for locoregional control. Clinical stage and Karnofsky index affected overall survival and tumor stage. EGFR affected locoregional control in the p16 negative subgroup. CONCLUSION: Our study confirmed the negative effect of CD44 and EGFR and the positive effect of p16 on radiotherapy results.
引用
- Slavik M, Shatokhina T, Sana J, et al. Expression of CD44, EGFR, p16, and their mutual combinations in patients with head and neck cancer: Impact on outcomes of intensity-modulated radiation therapy. Head Neck. 2018. PMID: 30552846. doi:10.1002/hed.25533
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。